Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome

详细信息    查看全文

• 作者：Wolfgang J. Mayer ; MD ; ^{wolfgang.j.mayer@med.uni-muenchen.de" class="auth_mail" title="E-mail the corresponding author} ; Stefanie Kurz ; MD ; Armin Wolf ; MD ; Daniel Kook ; MD ; Thomas Kreutzer ; MD ; Anselm Kampik ; MD ; Siegfried Priglinger ; MD ; Christos Haritoglou ; MD
• 刊名：Journal of Cataract & Refractive Surgery
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：41
• 期：9
• 页码：1954-1961
• 全文大小：1019 K

文摘

To investigate the effectiveness and safety of a dexamethasone implant (Ozurdex) to treat pseudophakic macular edema (Irvine-Gass syndrome).

Setting

Department of Ophthalmology, Ludwig-Maximilians-University Munich, Munich, Germany.

Design

Prospective nonrandomized study.

Methods

Preoperatively and in 12 monthly postoperative intervals, a complete ophthalmic examination was performed in study patients, including measurement of corrected distance visual acuity (CDVA) using the standard Early Treatment Diabetic Retinopathy Study chart, intraocular pressure, foveal thickness using spectral-domain optical coherence tomography (SD-OCT), and retinal sensitivity (mean defect depth) using microperimetry. Morphological aspects of the inner segment–outer segment junction and visual function were correlated.

Results

Twenty-three eyes (23 patients) with pseudophakic macular edema after uneventful cataract surgery were included. The mean duration of macular edema before treatment with a dexamethasone implant was 5.4 months (range 2 to 8 months). The CDVA increased in all patients from 30.2 letters ± 4.3 (SD) at baseline to 50.4 ± 4.9 letters at 12 months (P = .0016), regardless of the time of macular edema duration. Foveal thickness decreased from 520.8 ± 71.4 μm to 232.7 ± 26.6 μm (P < .002). Retinal sensitivity (mean defect depth) increased significantly over a 12-month follow-up, correlating positively with a restored inner segment–outer segment junction on SD-OCT analyses. No relevant adverse events were reported, and 9 recurrences occurred with a peak after 3 months and required a second dexamethasone implant injection.

Conclusion

The dexamethasone implant was safe and effective in treating pseudophakic macular edema regardless of the duration of the edema.

Financial Disclosure

Drs. Mayer and Haritoglou are consultants to Allergan, Inc. No author has a financial or proprietary interest in any material or method mentioned.